In summary, although additional confirmation is needed for breast, prostate, and colorectal cancers, genomic ascertainment showed generally lower (or not significant) risk than previously reported for individuals in the all-variant, PTV, and PMV groups in CHEK2 variants. Here, CHEK2 is linked to colorectal cancer.